Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

10.19 -0.53 (-4.90%)
Delayed Quote Updated: 10:52 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Ships One Millionth Gvoke® Unit
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
Xeris Biopharma to Participate at the Jefferies Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Reports First Quarter 2023 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 9, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
News headline image
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Appoints Ricki Fairley to Board of Directors
From Xeris Biopharma Holdings
Via Business Wire
News headline image
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
From Xeris Biopharma, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 8, 2023 ↗
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
News headline image
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Updates Its Outlook For 2022
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 63 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 35 companies reached new 52-week lows. 
Via Benzinga
News headline image
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 9, 2022 ↗
Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly earnings at $0.11 per share on revenue of $103.46 million. 
Via Benzinga
News headline image
Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
10 Best Medical Stocks Under $5 ↗
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the... 
Via Talk Markets
News headline image
Xeris Biopharma Posts Encouraging Data From Reformulated Thyroid Hormone Deficiency Treatment In Healthy Participants ↗
 
Via Benzinga
News headline image
Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast
From Xeris Biopharma Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.